Beschreibung
Carbamazepine reduces valproic acid levels through enzyme induction, while valproic acid inhibits epoxide hydrolase, increasing the toxic carbamazepine-10,11-epoxide metabolite.
Mechanismus
Carbamazepine induces CYP3A4, accelerating valproate metabolism; valproate inhibits epoxide hydrolase, causing accumulation of the carbamazepine 10,11-epoxide metabolite which causes neurotoxicity.
Klinische Bedeutung
Double-edged interaction: both subtherapeutic valproate and carbamazepine toxicity (diplopia, ataxia, nausea) are risks despite normal carbamazepine parent drug levels.
Maßnahmen
Monitor plasma levels of both drugs and the carbamazepine-10,11-epoxide metabolite; reduce carbamazepine dose if epoxide levels are high.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.